Martin Auster Analyst Performance

Managing Director Biotechnology at Raymond James Financial

Martin Auster is a stock analyst at Raymond James Financial in the medical sector, covering 18 publicly traded companies. Over the past year, Martin Auster has issued 7 stock ratings, including strong buy and buy recommendations. While full access to Martin Auster's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Martin Auster's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

53 Last 7 Years

Buy Recommendations

65.38% 34 Buy Ratings

Companies Covered

18 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	7.7%	4 ratings
Buy	57.7%	29 ratings
Hold	30.8%	16 ratings
Sell	3.8%	2 ratings

Out of 52 total stock ratings issued by Martin Auster at Raymond James Financial, the majority (57.7%) have been Buy recommendations, followed by 30.8% Hold, 7.7% Strong Buy, and 3.8% Sell.

Best & Worst Calls

• Best Call

  0000.0%

  RARX

  Oct 2018

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  ANAB

  Nov 2018

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	18 companies

Martin Auster, an analyst at Raymond James Financial, currently covers 18 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 18 companies	100.0%

Martin Auster of Raymond James Financial specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 8 companies	44.4%
MED - DRUGS 3 companies	16.7%
PHARMACEUTICAL PREPARATIONS 3 companies	16.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 3 companies	16.7%
MED - GENERIC DRG 1 company	5.6%

About Martin Auster

Martin Auster joined Raymond James in 2025 and covers the biotechnology industry. Previously, he served as chief financial officer at Ventyx biosciences from 2021-2024 and was a research analyst at UBS Securities LLC from 2016-2017 and at Credit Suisse Securities (USA) LLC from 2017-2021. Prior to that, Dr. Auster held the positions of chief business officer at Ascendis Pharma from 2014- 2016 and VP-business development & strategic finance at United Therapeutics Corp. from 2009-2014. Earlier in his career, he served as a senior equity analyst at Truist Securities, Inc., as a senior biotechnology analyst at Wachovia Securities LLC, and as a portfolio manager at GLG Partners, Inc. Dr. Auster completed his undergraduate degree at the University of Michigan and obtained a doctorate from the University of Texas Medical Branch at Galveston.

Follow on LinkedIn

Martin Auster's Ratings History at Raymond James Financial

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
BBIO BridgeBio Pharma	10/21/2025	Boost Price Target	$54.90	$59.00	Outperform	$0.00 00.00% ROI
IRON Disc Medicine	10/17/2025	Boost Price Target	$92.36	$108.00	Strong-Buy	$0.00 00.00% ROI
ASND Ascendis Pharma A/S	10/17/2025	Initiated Coverage	$207.03	$271.00	Strong-Buy	$0.00 00.00% ROI
ASND Ascendis Pharma A/S	10/16/2025	Upgrade	$210.50		Strong-Buy	$0.00 00.00% ROI
DYN Dyne Therapeutics	8/25/2025	Upgrade	$12.58	$35.00	Strong-Buy	$0.00 00.00% ROI
ALNY Alnylam Pharmaceuticals	7/30/2025	Initiated Coverage	$330.55	$370.00	Outperform	$0.00 00.00% ROI
DYN Dyne Therapeutics	7/29/2025	Reiterated Rating	$9.14	$31.00	Outperform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.